| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692 Fundación de investigación HM | Recruiting | Phase 1, Phase 2 | September 20, 2024 |
| Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors NCT05687123 National Cancer Institute (NCI) | Recruiting | Phase 1 | August 14, 2024 |
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. NCT06379217 Novartis Pharmaceuticals | Active, not recruiting | Phase 1 | July 29, 2024 |
| A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms NCT06398444 Sinotau Pharmaceutical Group | Recruiting | Phase 2, Phase 3 | June 11, 2024 |
| Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors NCT06016855 Vanderbilt-Ingram Cancer Center | Recruiting | Phase 4 | May 31, 2024 |
| 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry NCT06395402 University of Iowa | Recruiting | Phase 2 | May 3, 2024 |
| Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort NCT06256705 Assistance Publique - Hôpitaux de Paris | Recruiting | N/A | March 25, 2024 |
| Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial NCT05773274 National Cancer Institute (NCI) | Recruiting | Phase 2 | January 12, 2024 |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells NCT05691465 National Cancer Institute (NCI) | Recruiting | Phase 2 | December 27, 2023 |
| Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications NCT06121271 University College, London | Not yet recruiting | Phase 2 | December 18, 2023 |
| A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs NCT07057622 HTA Co., Ltd. | Recruiting | Phase 3 | December 12, 2023 |
| Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors NCT05724108 National Cancer Institute (NCI) | Active, not recruiting | Phase 2 | August 30, 2023 |
| Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer NCT05583708 Weill Medical College of Cornell University | Recruiting | Phase 2 | August 3, 2023 |
| Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial NCT05247905 Alliance for Clinical Trials in Oncology | Active, not recruiting | Phase 2 | February 16, 2023 |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors NCT04665739 National Cancer Institute (NCI) | Recruiting | Phase 2 | February 3, 2023 |
| Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors NCT05249114 Providence Health & Services | Active, not recruiting | Phase 1 | December 28, 2022 |
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors NCT05278208 Nationwide Children's Hospital | Recruiting | Phase 1, Phase 2 | November 21, 2022 |
| Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) NCT04086485 National Cancer Institute (NCI) | Recruiting | Phase 1, Phase 2 | October 3, 2022 |
| Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs NCT04711135 Advanced Accelerator Applications Results posted | Active, not recruiting | Phase 2 | August 31, 2022 |
| A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs NCT05459844 Sinotau Pharmaceutical Group | Active, not recruiting | Phase 3 | August 31, 2022 |
| A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab NCT05142696 Novartis Pharmaceuticals | Active, not recruiting | Phase 1, Phase 2 | July 13, 2022 |
| Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors NCT05870423 Erasmus Medical Center | Recruiting | Phase 1 | June 1, 2022 |
| A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. NCT05109728 Novartis Pharmaceuticals | Active, not recruiting | Phase 1 | May 10, 2022 |
| Lutathera and ASTX727 in Neuroendocrine Tumours NCT05178693 Imperial College London | Recruiting | Phase 1 | April 25, 2022 |
| PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours NCT05053854 Peter MacCallum Cancer Centre, Australia | Recruiting | Phase 1 | December 8, 2021 |
| Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET NCT04954820 Institut du Cancer de Montpellier - Val d'Aurelle | Recruiting | Phase 2 | October 18, 2021 |
| Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases NCT04837885 University Hospital, Bordeaux | Recruiting | Phase 2 | September 24, 2021 |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors NCT04750954 National Cancer Institute (NCI) | Active, not recruiting | Phase 1 | July 22, 2021 |
| 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma NCT04903899 Jakob Stenman | Recruiting | Phase 2 | May 19, 2021 |
| Spanish Series of Patients Treated With the Radionuclide Lutetium177 NCT04949282 Sociedad Española de Medicina Nuclear e Imagen Molecular | Recruiting | — | May 10, 2021 |
| Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery NCT04609592 Stanford University | Active, not recruiting | Phase 1 | March 17, 2021 |
| Targeted Therapy and Avelumab in Merkel Cell Carcinoma NCT04261855 Melanoma and Skin Cancer Trials Limited | Active, not recruiting | Phase 1, Phase 2 | October 8, 2020 |
| Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver NCT04544098 Memorial Sloan Kettering Cancer Center | Active, not recruiting | Early phase 1 | September 2, 2020 |
| Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors NCT04234568 National Cancer Institute (NCI) Results posted | Active, not recruiting | Phase 1 | July 20, 2020 |
| Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy NCT04082520 Mayo Clinic | Recruiting | Phase 2 | April 14, 2020 |
| Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients NCT04917484 Tine Gregersen, MD | Recruiting | Phase 2 | February 1, 2020 |
| Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET NCT03972488 Advanced Accelerator Applications Results posted | Active, not recruiting | Phase 3 | January 8, 2020 |
| PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial) NCT07185672 Tata Memorial Hospital | Recruiting | Phase 3 | August 7, 2019 |
| Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma NCT03971461 NYU Langone Health | Active, not recruiting | Phase 2 | May 15, 2019 |
| Post-Authorization Long-Term Safety Study of LUTATHERA NCT03691064 Advanced Accelerator Applications | Active, not recruiting | — | November 28, 2018 |